The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.